Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,466 | 0,492 | 18:25 | |
0,466 | 0,492 | 18:25 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
15:02 | RedChip Companies, Inc.: BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 150 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big... ► Artikel lesen | |
Di | FibroBiologics, Inc.: FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa | 2 | GlobeNewswire (USA) | ||
12.09. | FibroBiologics, Inc.: FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies | 2 | GlobeNewswire (USA) | ||
12.09. | H.C. Wainwright bestätigt Kaufempfehlung für FibroBiologics und Kursziel von 10 US-Dollar | 5 | Investing.com Deutsch | ||
12.09. | FibroBiologics stock price target maintained at $10 by H.C. Wainwright | 1 | Investing.com | ||
11.09. | FibroBiologics, Inc.: FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment | 1 | GlobeNewswire (USA) | ||
10.09. | FibroBiologics, Inc.: FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies | 100 | GlobeNewswire (Europe) | HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the... ► Artikel lesen | |
01.08. | FibroBiologics reports 1H results | 5 | Seeking Alpha | ||
31.07. | FibroBiologics, Inc.: FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 177 | GlobeNewswire (Europe) | HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development... ► Artikel lesen | |
31.07. | FibroBiologics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
28.07. | FibroBiologics files patent for multipotent cell generation method | 2 | Investing.com | ||
28.07. | FibroBiologics, Inc.: FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications | 2 | GlobeNewswire (USA) | ||
18.07. | FibroBiologics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.07. | RedChip Companies, Inc.: Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 464 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / July 11, 2025 / RedChip Companies will air interviews with Brag House Holdings, Inc. (NASDAQ:TBH) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks,... ► Artikel lesen | |
11.07. | FibroBiologics, Inc.: FibroBiologics to Present at the Advanced Wound Care Summit USA | 2 | GlobeNewswire (USA) | ||
07.07. | FibroBiologics, Inc.: FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 | 1 | GlobeNewswire (USA) | ||
03.07. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
03.07. | RedChip Companies, Inc.: Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 416 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks... ► Artikel lesen | |
16.06. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
16.06. | FibroBiologics, Inc.: FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 83,50 | -0,77 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., Tübingen | Datum der Anmeldung:18.09.2025Aktenzeichen:B3-86/25Unternehmen:BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., TübingenProduktmärkte:biotechnologische... ► Artikel lesen | |
CUREVAC | 4,556 | -0,61 % | CureVac-Aktie vor FINANZ-DRAMA: Droht ein neuer Crash?!! | ||
MODERNA | 20,690 | -2,04 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
PAION | 0,015 | -28,97 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NOVAVAX | 7,040 | -1,63 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NANOREPRO | 1,770 | -0,56 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
4SC | 0,872 | -2,02 % | HV-Termine: Hauptversammlungen u.a. bei 4SC, Bastei Lübbe, Janosch, Koch, mVISE, One Touch Football | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 2,040 | -1,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
INFLARX | 1,124 | +2,00 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
DEFENCE THERAPEUTICS | 0,490 | +3,38 % | Defence Therapeutics Inc.: Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin | Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,476 | -1,37 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
DYNAVAX | 8,400 | +0,62 % | Dynavax Technologies: Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile | At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited... ► Artikel lesen | |
IBIO | 0,685 | +0,74 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen |